Colcrys, Gloperba, Mitigare (colchicine) is a small molecule pharmaceutical. Colchicine was first approved as Colcrys on 2009-07-29. It is used to treat amyloidosis, biliary liver cirrhosis, familial mediterranean fever, and gout in the USA. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target glycine receptor subunit alpha-1, bromodomain-containing protein 4, and glycine receptor subunit alpha-2. Probenecid and colchicine's patents are valid until 2037-12-20 (FDA).
|Trade Name||Colcrys, Gloperba, Mitigare|
|Indication||amyloidosis, biliary liver cirrhosis, familial mediterranean fever, gout|